XtalPi and CK Life Sciences are collaborating on tumor vaccine research and development

XtalPi entered into a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. The goal is to jointly develop a new artificial intelligence (AI) tumor vaccine R&D platform. This will improve tumor detection and design capabilities vaccines and accelerate the development of more types of vaccines.

According to public information, there were almost 20 million new diagnoses cancer patients worldwide in 2021, from which approximately 4.5 million cases originate China. Many types of cancer lead to adverse outcomes with high morbidity and mortality, and a large unmet clinical need remains.

According to Mordor Intelligence, the global cancer vaccine market was valued at $6.79 billion in 2021 and will grow at a CAGR of 11.53% from 2022 to 2026. The expected size of the market by 2026 will be approximately $12 billion.

Tumor vaccines targeting various tumor neoantigens, tumor-associated antigens (TAA) and tumor-specific antigens (TSA) in patients can be developed for use as immunotherapy to activate the patient’s own specific immune responses.

Currently, there are only two therapeutic tumor vaccines, Sipuleutsel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as prophylactic human papillomavirus and hepatitis B tumor vaccines approved by the Food and Drug Administration. drugs of the USA (FDA).

Recently, several other tumor vaccines have entered clinical development, and evidence of their efficacy has begun to emerge.

Building an R&D platform

Currently, the development and preclinical process of cancer vaccine development is complex and lengthy, which hinders the efficiency and success of cancer vaccine research and development.

Combining XtalPi’s industry expertise in AI computing and robotic automation, this collaboration aims to create an AI tumor vaccine research platform that applies advanced AI algorithms and high-precision molecular modeling to predict and develop a variety of tumor vaccines that can activate specific immune responses to kill tumors.

Tumor vaccines will be screened and validated through automated experiments, and by integrating algorithmic feedback to optimize activity and efficacy, the platform is expected to generate preclinical tumor vaccine candidates with strong immune activity.

Improving academic performance

Shuhao Wen, co-founder and chairman of XtalPi, said: “As a company headquartered in Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, XtalPi aims to realize the interaction between Shenzhen and Hong Kong by creating a new paradigm for innovation in the Greater Bay Area. With the latest technological advances in automation, artificial intelligence is accelerating the development of more innovative and diverse areas of drug research and development.

“Together with CK Life Sciences, we aim to overcome conventional limitations and discover diverse applications of advanced technologies. We believe that the cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to advance vaccine research and development and accelerate key stages of cancer vaccine development. We are confident that this collaboration will greatly facilitate the exchange of scientific research in the Greater Bay Area.”

Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, added: “The research and development of cancer vaccines is one of the key areas of development for CK Life Sciences. In collaboration with XtalPi, XtalPi’s artificial intelligence algorithm, molecular modeling and automated experiments will be applied to accelerate the research and development process, increase the success rate and increase the effectiveness of tumor vaccines.” XtalPi and CK Life Sciences are collaborating on tumor vaccine research and development

Back to top button